Is Wall Street Underestimating HCA Healthcare Stock’s Potential?
HCA Healthcare (HCA) stock is at an interesting point right now. It is trading at attractive valuation, and if you bet on it, you are betting on a company that’s growing reasonably, is sustaining good cash flow and margin, has low-debt to market capitalization structure, and is relatively cheaply valued. But is that enough?
Why Bet On HCA Now?
HCA is leveraging its dominant scale and network density in high-growth urban markets to capture a greater share of profitable outpatient and high-acuity services. This strategy, combined with superior operational efficiencies and significant capital returns, creates a durable, compounding investment vehicle likely capable of navigating near-term reimbursement pressures.
- HCA holds the #1 or #2 inpatient market share in approximately 80% of its markets.
- The company is actively targeting a market share increase from 27% to 29% by 2030.
- Outpatient services, which are growing faster than inpatient services, now account for approximately 38.3% of total patient revenues.
- Management has authorized a new $10 billion share repurchase program, signaling confidence in future cash flow generation.
How Do The Fundamentals Look?
- Revenue Growth: 6.7% LTM and 7.9% last 3 year average.
- Operating Margin: Nearly 15.1% 3-year average operating margin.
- No Margin Shock: HCA Healthcare has improved in the last 12 months. Although the latest Q1 2026 operating margin was 12.0%, down from 12.7% in Q1 2025.
- Modest Valuation: Despite these fundamentals, HCA stock trades at a PE multiple of 14.1
Below is a quick comparison of HCA fundamentals with S&P medians.
| HCA | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Facilities | – |
| PE Ratio | 14.1 | 24.0 |
|
|
||
| LTM* Revenue Growth | 6.7% | 7.2% |
| 3Y Average Annual Revenue Growth | 7.9% | 5.6% |
| LTM Operating Margin Change | 0.5% | 0.0% |
|
|
||
| LTM* Operating Margin | 15.7% | 18.4% |
| 3Y Average Operating Margin | 15.1% | 18.3% |
| LTM* Free Cash Flow Margin | 10.4% | 14.5% |
*LTM: Last Twelve Months
The Bear View & The Current Investment Debate
The current investment debate on HCA is centered around: Can HCA’s scale and efficiency offset a direct $600M-$900M EBITDA headwind from ACA policy changes, or will payer mix deterioration finally break its compounding growth story?
The prevailing sentiment is bullish. Known headwinds are priced. Management’s consistent beat-and-raise history and massive buyback signal confidence. The market is rewarding HCA as a resilient compounder, not just a hospital subject to policy whims.
| Bull View | Bear View |
|---|---|
| HCA’s ‘resiliency program’ and operational excellence will absorb the guided ACA headwind, allowing for continued 2-3% patient volume growth and margin stability, proving its ‘all-weather’ thesis. | The payer mix shift from the ACA changes will be worse than guided, causing the EBITDA impact to exceed $900M and leading to a 2026 earnings miss. |
You can evaluate more on which view to bet on by visiting HCA Investment Highlights & Full Analysis
HCA Is Just One of Several Such Stocks
Not ready to act on HCA? Consider these alternatives:
These stocks have strong operating margin, and are trading meaningfully below 1Y high with P/E below S&P 500 median and P/S below historical average.
A portfolio that was built starting 12/31/2016 with stocks that fulfill the criteria above would have resulted in average 6-month and 12-month forward returns of 12.7% and 25.8% respectively, with win rate (percentage of picks returning positive) of above 70%.
Portfolios Are The Smarter Way To Invest
Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.